Loading
A phase 2 trial of durvalumab, capecitabine, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by Peking Union Medical College Hospital, now recruiting.
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer. is a phase 2, randomised interventional study registered as NCT07679399 by Peking Union Medical College Hospital, with a registry enrolment figure of 222 participants, started 2025-06-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: Durvalumab plus GEMOX/GC chemotherapy sequentially followed by lenvatinib, Capecitabine. Conditions listed: Biliary Tract Neoplasms Immunotherapy. Gallbladder cancer is named in the registry entry: "3. Histologically confirmed cholangiocarcinoma or gallbladder cancer (excluding pancreatic cancer or ampullary cancer)". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenvatinib, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Lenvatinib, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Lenvatinib, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Lenvatinib, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Ampullary cancer (ampulla of Vater), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/